|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Biomarker Analysis to Identify Molecular Signatures Predictive of Response in the COMBAT Study |
Alicia Morgans, MD, MPH and Emmanuel Antonarakis, MD
Alicia Morgans and Emmanuel Antonarakis discuss an ongoing biomarker analysis aimed at identifying a molecular signature predictive of response in the COMBAT study. |
|
|
|
|
|
|
|
|
|
|
| Bipolar Androgen Therapy in the Management of Prostate Cancer |
Samuel Denmeade, MD
Samuel Denmeade, Co-Director of the Johns Hopkins Prostate Cancer Program joins Alicia Morgans in a discussion on Bipolar Androgen Therapy (BAT) for prostate cancer. The pair discuss the ideal patient population for this treatment and its benefits suggesting that the physical vitality of patients could be maintained on BAT. |
|
|
|
|
|
|
|
|
|
|
| Baseline Pathogenic Mutations in Metastatic Castration-Resistant Prostate Cancer Patients Being Treated with High-Dose Testosterone
|
| Oliver Sartor, MD
|
| Oliver Sartor joins Alicia Morgans to discuss baseline pathogenic mutations in patients who being treated with high-dose testosterone.
|
|
|
|
|
|
|
|
|
|
|
|
| Overall Survival and Biomarker Results From Combat: A Phase 2 Study of Bipolar Androgen Therapy Plus Nivolumab for Patients With Metastatic Castrate-Resistant Prostate Cancer |
| Mark Markowski, MD, Ph.D. |
Mark Markowski discusses bipolar androgen therapy (BAT) in patients with metastatic castrate-resistant prostate cancer (mCRPC). Based on the data, there are favourable outcomes of the combination of BAT and nivolumab in heavily pretreated patients with mCRPC, with a median overall survival of exceeding 2 years and durable responses in a subset of patients.
|
|
|
|
|
|
| Bipolar Androgen Therapy in Advanced Prostate Cancer
|
| Laura Anne Sena, MD, Ph.D.
|
| Laura Sena discusses the recent advances in the field of bipolar androgen therapy in advanced prostate cancer. Dr. Sena began her talk by noting that the concept of testosterone supplementation causing a paradoxical suppression of castration-resistant prostate cancer cell growth is not necessarily a novel one. She reviews several trials in this space and offers five questions that remail for further development of BAT.
|
|
|
|
|
|
|
|
|
|
|
| COMBAT-CRPC: COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC |
| Mark. Markowski, MD, PhD, |
| Mark Markowski reports the results of a prospective phase 2 study of men with mCRPC treated with BAT in combination with nivolumab. BAT plus nivolumab was well-tolerated without concerning safety signals. The combination met the pre-specified primary endpoint of confirmed PSA50 response in a heavily treated population. Durable responses were observed in a subset of patients and a biomarker analysis is ongoing to identify a molecular signature predictive of response. |
|
|
|
|
|
| Bipolar Androgen Therapy (BAT) Plus Olaparib in Men With Metastatic Castration-Resistant Prostate Cancer |
| Michael Schweizer, MD |
| Michael Schweizer describes a single-center phase II trial testing olaparib in combination with Bipolar Androgen Therapy (BAT) for men with metastatic castration-resistant prostate cancer (mCRPC). BAT leads to a rapid fluctuation in testosterone (T) between near-castrate and supraphysiologic levels and has shown promise in mCRPC. Additionally, it’s postulated that BAT effects may be mediated through induction of DNA damage. |
|
|
|
|
|
 |
